viewImmuPharma PLC

Immupharma PLC - Incanthera announces Rule 23 Notice re NEX listing

RNS Number : 1304D
Immupharma PLC
17 February 2020


ImmuPharma PLC

("ImmuPharma" or the "Company")


Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that the NEX Exchange Growth Market ("NEX") has today released a pre-admission announcement under Rule 23 of the intention of Incanthera plc ("Incanthera"), a specialist oncology company, to quote on NEX.

ImmuPharma currently holds a 14.0% shareholding in Incanthera following its subscription for shares in September 2018. Following admission, ImmuPharma will retain 7,272,740 shares in Incanthera, representing 11.9%.

At the time of the subscription, ImmuPharma was also granted warrants to subscribe for additional ordinary shares in Incanthera at any time over five years from the initial subscription. These warrants have been carried over into the new listed plc company and now total 7,272,740 warrants. The exercise price has been rebased to the issue price.

Commenting on the announcement, Dimitri Dimitrou, CEO of ImmuPharma said:

"We are delighted to note Incanthera's imminent quote on NEX. 

"Incanthera's diverse oncology pipeline has blockbuster potential. We are confident of the medium to long term prospects of the business, but we are particularly excited at the potential near term commercialisation of the lead product Sol, for skin cancer and other topical indications.

"As a major shareholder, with a tangible stake in the future success of Incanthera, we look forward to the creation of further value for our shareholders as Incanthera moves forward".

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR").



For further information please contact:


ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496



SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin, Henry Todd


Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes


SI Capital (Joint Broker)

Nick Emerson



+44 (0) 203 368 8974



+44 (0) 203 815 8880



+44 (0) 1483 413500



4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy


Degroof Petercam (Liquidity Provider)

Erik De Clippel


Backstage Communication

Olivier Duquaine

Jean-Louis Dubrule

+32 (0) 2 747 02 60



+32 (0) 2 287 95 34




+32 (0) 477 504 784

+32 (0) 497 50 84 03








Notes to Editors



About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, LupuzorTM, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.


About Incanthera Limited


Incanthera Limited was formed in 2010 as a spin-out from the Institute of Cancer Therapeutics at Bradford University and is targeting the treatment of cancer through a portfolio of unique technologies. Having successfully commercialised its lead product in 2017, it is actively acquiring and developing technologies to further enhance its portfolio of cancer therapeutics. For more information, please visit www.incanthera.com


About NEX


NEX Exchange (formerly known as ISDX) is the ICAP Securities and Derivatives Exchange.  The NEX Exchange Growth Market is an equity market for small and medium-sized ambitious, growth enterprises.  Typically its admission requirements are less stringent than those for quoting on AIM.


In accordance with Rule 23 of the Growth Market Rules, a NEX Exchange Corporate Adviser must submit the information no less than 10 business days prior to the intended admission date, and NEX Exchange will release the pre-admission announcement by RIS under the heading "NEX Exchange" on the date of submission of the form.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: ImmuPharma PLC

Price: 14

Market: AIM
Market Cap: £25.62 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Immupharma chairman 'delighted' with first significant investment from...

ImmuPharma PLC's (LON:IMM) Tim McCarthy speaks to Proactive London's Andrew Scott following the news of new funding through two specialist US healthcare investors. Up to US$6.3mln is being invested into IMM from an issue of unsecured convertible securities and associated options to L1 Capital...

on 15/6/20